GS-441524 is a nucleoside analog antiviral drug. It is a prodrug of the active antiviral compound known as GS-443902. GS-441524 is closely related to RDV, which gained attention during the COVID-19 pandemic as a potential treatment for SARS-CoV-2, the virus that causes COVID-19.
GS-441524 was initially developed by Gilead Sciences for the treatment of RNA virus infections. These compounds work by inhibiting the viral RNA-dependent RNA polymerase, which is crucial for the replication of certain RNA viruses.
One of the notable applications of GS-441524 has been in veterinary medicine, particularly in the treatment of feline infectious peritonitis (FIP). FIP is caused by a coronavirus in cats, and GS-441524 has shown promise in inhibiting the replication of this virus.
| Parameters | Specifications |
|---|---|
| GS441 FIP Treatment | GS441524 |
| Molecular Weight | C12H13N5O4 |
| Shipping Method | Air(UPS, FedEx, TNT, EMS) Or Sea |
| Product Usage | Cat FIPV Treatment |
| Specification | 20mg/tablets, 40mg/tablets, Or Customized |
| CAS | 1191237-69-0 |
| Product Type | Tablets |
| Product Packaging | 10 Tablets Per Bag |
| Product Shelf Life | 1 Years |
| Product Form | Tablets |
| Product Storage | Store In A Cool, Dry Place |